These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 29542165)
1. MAGI2 is an independent predictor of biochemical recurrence in prostate cancer. David SN; Arnold Egloff SA; Goyal R; Clark PE; Phillips S; Gellert LL; Hameed O; Giannico GA Prostate; 2018 Jun; 78(8):616-622. PubMed ID: 29542165 [TBL] [Abstract][Full Text] [Related]
2. MAGI-2 in prostate cancer: an immunohistochemical study. Goldstein J; Borowsky AD; Goyal R; Roland JT; Arnold SA; Gellert LL; Clark PE; Hameed O; Giannico GA Hum Pathol; 2016 Jun; 52():83-91. PubMed ID: 26980016 [TBL] [Abstract][Full Text] [Related]
3. Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma. Gettman MT; Pacelli A; Slezak J; Bergstralh EJ; Blute M; Zincke H; Bostwick DG Urology; 1999 Sep; 54(3):479-85. PubMed ID: 10475358 [TBL] [Abstract][Full Text] [Related]
4. Tertiary Gleason pattern 5 is a powerful predictor of biochemical relapse in patients with Gleason score 7 prostatic adenocarcinoma. Hattab EM; Koch MO; Eble JN; Lin H; Cheng L J Urol; 2006 May; 175(5):1695-9; discussion 1699. PubMed ID: 16600733 [TBL] [Abstract][Full Text] [Related]
5. High-grade prostatic intraepithelial neoplasia is an independent predictor of outcome after radical prostatectomy. Pierorazio PM; Lambert SM; Matsukhani M; Sprenkle PC; McCann TR; Katz AE; Olsson CA; Benson MC; McKiernan JM BJU Int; 2007 Nov; 100(5):1066-70. PubMed ID: 17784880 [TBL] [Abstract][Full Text] [Related]
6. Comparative study of immunohistochemical expression of ERG and MAGI2 in prostatic carcinoma. Dawoud MM; Aiad HA; Bahbah AMNH; Shaban MI Ann Diagn Pathol; 2021 Jun; 52():151727. PubMed ID: 33713943 [TBL] [Abstract][Full Text] [Related]
7. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma. Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760 [TBL] [Abstract][Full Text] [Related]
8. The role of high-grade prostatic intraepithelial neoplasia for biochemical relapse of prostate carcinoma after radical prostatectomy. Auskalnis S; Milonas D; Jievaltas M; Vaiciūnas K; Mickevicius A; Gudinaviciene I Medicina (Kaunas); 2010; 46(9):604-10. PubMed ID: 21252594 [TBL] [Abstract][Full Text] [Related]
9. The relationship between the extent of surgical margin positivity and prostate specific antigen recurrence in radical prostatectomy specimens. Marks RA; Koch MO; Lopez-Beltran A; Montironi R; Juliar BE; Cheng L Hum Pathol; 2007 Aug; 38(8):1207-11. PubMed ID: 17490720 [TBL] [Abstract][Full Text] [Related]
10. Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer. Bañez LL; Sun L; van Leenders GJ; Wheeler TM; Bangma CH; Freedland SJ; Ittmann MM; Lark AL; Madden JF; Hartman A; Weiss G; Castaños-Vélez E J Urol; 2010 Jul; 184(1):149-56. PubMed ID: 20478579 [TBL] [Abstract][Full Text] [Related]
11. Presence or absence of a positive pathological margin outperforms any other margin-associated variable in predicting clinically relevant biochemical recurrence in Gleason 7 prostate cancer. Huang JG; Pedersen J; Hong MK; Harewood LM; Peters J; Costello AJ; Hovens CM; Corcoran NM BJU Int; 2013 May; 111(6):921-7. PubMed ID: 23350712 [TBL] [Abstract][Full Text] [Related]
12. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients. Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093 [TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database. Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968 [TBL] [Abstract][Full Text] [Related]
14. Overexpression of Cdc20 in clinically localized prostate cancer: Relation to high Gleason score and biochemical recurrence after laparoscopic radical prostatectomy. Mao Y; Li K; Lu L; Si-Tu J; Lu M; Gao X Cancer Biomark; 2016; 16(3):351-8. PubMed ID: 26889981 [TBL] [Abstract][Full Text] [Related]
15. Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer. Lee CT; Capodieci P; Osman I; Fazzari M; Ferrara J; Scher HI; Cordon-Cardo C Clin Cancer Res; 1999 May; 5(5):977-83. PubMed ID: 10353729 [TBL] [Abstract][Full Text] [Related]
16. Clinical features and prognosis of prostate cancer with high-grade prostatic intraepithelial neoplasia. Lee D; Lee C; Kwon T; You D; Jeong IG; Hong JH; Ahn H; Kim CS Korean J Urol; 2015 Aug; 56(8):565-71. PubMed ID: 26279825 [TBL] [Abstract][Full Text] [Related]
17. The significance of monoamine oxidase-A expression in high grade prostate cancer. Peehl DM; Coram M; Khine H; Reese S; Nolley R; Zhao H J Urol; 2008 Nov; 180(5):2206-11. PubMed ID: 18804811 [TBL] [Abstract][Full Text] [Related]
18. Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens. Cheng L; Poulos CK; Pan CX; Jones TD; Daggy JK; Eble JN; Koch MO J Urol; 2005 Sep; 174(3):898-902. PubMed ID: 16093983 [TBL] [Abstract][Full Text] [Related]
19. Use of interphase fluorescence in situ hybridization in prostate needle biopsy specimens with isolated high-grade prostatic intraepithelial neoplasia as a predictor of prostate adenocarcinoma on follow-up biopsy. Bastacky S; Cieply K; Sherer C; Dhir R; Epstein JI Hum Pathol; 2004 Mar; 35(3):281-9. PubMed ID: 15017583 [TBL] [Abstract][Full Text] [Related]
20. Visual estimation of tumour extent is not an independent predictor of prostate specific antigen recurrence. Jones TD; Koch MO; Lin H; Cheng L BJU Int; 2005 Dec; 96(9):1253-7. PubMed ID: 16287440 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]